{"id":"W4408979626","doi":"10.1016/s1556-0864(25)00323-5","title":"128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC)","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Docetaxel; Oncology; Internal medicine; Open label; Randomized controlled trial; Chemotherapy; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001639924,0.002130972,0.002548081,0.0004518438,0.0004692399,0.001687945,0.001308469,0.001890415,0.0108415],"category_scores_gemma":[0.0008676899,0.0007456956,0.002403861,0.0004628755,0.00134266,0.001337458,0.0006736378,0.005922048,0.002595544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001131265,"about_ca_system_score_gemma":0.001551292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285603,"about_ca_topic_score_gemma":0.004629777,"domain_scores_codex":[0.9995478,0.0001908686,0.0000194711,0.000091141,0.00003262087,0.0001181081],"domain_scores_gemma":[0.9994979,0.00006485645,0.0000808698,0.00003331152,0.00003064812,0.0002924599],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8905986,0.01569217,0.002105776,0.001493139,0.001951494,0.00008227315,0.0001416278,0.001459175,0.0111787,0.0004096341,0.007310282,0.06757718],"study_design_scores_gemma":[0.9173191,0.07665251,0.002465688,0.00003567745,0.0004706036,0.00006141808,0.000035068,0.0005370483,0.000552388,0.0001784873,0.001670988,0.00002111784],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9717026,0.005874359,0.00109201,0.002296412,0.000907239,0.006481254,0.005318654,0.0006359045,0.005691634],"genre_scores_gemma":[0.9667487,0.003984732,0.003024541,0.003212914,0.000451744,0.006556315,0.007562234,0.0001269962,0.00833174],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0108415,"threshold_uncertainty_score":0.03626841,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01942126379849149,"score_gpt":0.3984094260727004,"score_spread":0.3789881622742089,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}